Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Atrys Health, S.A. (ATRY.MC)
Madrid, ES
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.90% | -0.18% | -0.18% | -4.90% | +3.87% | -3.92% | +2.74% | -42.55% | -67.64% | +75.94% | +75.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-33.7% Q4'25: -72.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-214.3% Q4'25: -300.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-29.2% Q4'25: -59.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-26.4% Q4'25: -167.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-12.8% ★ Q4'25: -49.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.4% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-15.78× Q4'25: -1.55× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.29M
est: 11.97M (-39.0%)
|
14.84M
est: 14.46M (+2.6%)
|
33.81M
est: 33.00M (+2.4%)
|
121.01M
est: 134.62M (-10.1%)
|
158.37M
est: 196.90M (-19.6%)
|
201.57M
est: 211.11M (-4.5%)
|
212.74M
est: 216.60M (-1.8%)
|
141.01M
est: 229.15M (-38.5%)
|
172.80M
169.74M – 176.08M
-24.6% YoY
|
184.25M
181.66M – 187.47M
+6.6% YoY
|
206.61M
203.34M – 210.37M
+12.1% YoY
|
191.00M
187.98M – 194.48M
-7.6% YoY
|
| EBITDA |
1.96M
est: 1.43M (+36.9%)
|
3.17M
est: 1.73M (+83.0%)
|
6.68M
est: 3.95M (+69.0%)
|
5.87M
est: 16.13M (-63.6%)
|
16.63M
est: 23.60M (-29.5%)
|
31.91M
est: 13.97M (+128.5%)
|
19.07M
est: 14.33M (+33.1%)
|
-9.96M
est: 15.16M (-165.7%)
|
11.43M
11.23M – 11.65M
-24.6% YoY
|
12.19M
12.02M – 12.40M
+6.6% YoY
|
13.67M
13.45M – 13.92M
+12.1% YoY
|
12.64M
12.44M – 12.87M
-7.6% YoY
|
| EBIT |
673.1K
est: -294.2K (+328.7%)
|
1.27M
est: -355.6K (+455.9%)
|
3.21M
est: -811.5K (+496.1%)
|
-14.91M
est: -3.31M (-350.5%)
|
-9.35M
est: -4.84M (-93.0%)
|
2.24M
est: -20.34M (+111.0%)
|
-9.97M
est: -20.87M (+52.2%)
|
-37.18M
est: -22.08M (-68.4%)
|
-16.65M
-16.96M – -16.35M
+24.6% YoY
|
-17.75M
-18.06M – -17.50M
-6.6% YoY
|
-19.90M
-20.27M – -19.59M
-12.1% YoY
|
-18.40M
-18.74M – -18.11M
+7.6% YoY
|
| Net Income |
12.0K
est: 4.94M (-99.8%)
|
-104.8K
est: 5.23M (-102.0%)
|
-5.55M
est: 3.03M (-283.3%)
|
-23.20M
est: 10.99M (-311.1%)
|
-23.15M
est: 4.11M (-663.2%)
|
-45.59M
est: -31.51M (-44.7%)
|
-31.77M
est: -4.94M (-542.7%)
|
-100.30M
est: -23.86M (-320.3%)
|
1.45M
1.07M – 1.84M
+106.1% YoY
|
6.65M
6.34M – 6.95M
+357.5% YoY
|
10.58M
7.75M – 13.40M
+59.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
2.36M
est: 1.23M (+92.3%)
|
4.17M
est: 1.48M (+181.3%)
|
213.0K
est: 3.38M (-93.7%)
|
28.16M
est: 13.79M (+104.1%)
|
18.79M
est: 20.17M (-6.8%)
|
29.70M
est: 21.36M (+39.0%)
|
1.55M
est: 21.92M (-92.9%)
|
—
est: 23.19M (-100.0%)
|
17.49M
17.18M – 17.82M
-24.6% YoY
|
18.64M
18.38M – 18.97M
+6.6% YoY
|
20.91M
20.58M – 21.29M
+12.1% YoY
|
19.33M
19.02M – 19.68M
-7.6% YoY
|
| EPS |
0.00
est: 0.07 (-99.1%)
|
0.00
est: 0.07 (-107.1%)
|
-0.20
est: 0.04 (-600.0%)
|
-0.43
est: 0.15 (-396.0%)
|
-0.34
est: 0.05 (-747.9%)
|
-0.60
est: -0.41 (-44.6%)
|
-0.42
est: -0.07 (-546.2%)
|
-1.32
est: -0.24 (-453.4%)
|
0.02
0.01 – 0.02
+108.0% YoY
|
0.09
0.08 – 0.09
+357.6% YoY
|
0.14
0.10 – 0.18
+59.1% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlos Cordon-Cardo | Founder & Scientific Vice President | — | — |
| Inigo Valcaneras | Director of Operations | — | — |
| Isabel Lozano Fernandez | Executive Director | — | female |
| Jose Maria Huch Ginesta | Chief Financial Officer | — | male |
| Luis Duran | Global Chief Technology Officer | — | — |
| Marian Isach | Chief Executive Officer | — | female |
| Pedro Salord | People Director | — | — |
| Roberto Lapieza | Sales Director | — | — |
| Santiago De Torres Sanahuja | Executive Chairman | — | male |
| Zvi Fuchs | Founder and Medical Vice President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATRY.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
